论文部分内容阅读
目的:探讨参苓白术散口服联合柳氮磺胺吡啶(SASP)灌肠治疗慢性型溃疡性结肠炎患者的疗效。方法:将56例慢性复发型溃疡性结肠炎(UC)患者随机分为观察组和对照组,各28例。观察组给予参苓白术散口服(18g/d)联合柳氮磺胺吡啶灌肠(3g/d)治疗8周,随访半年;对照组只给予柳氮磺胺吡啶灌肠(3g/d),治疗8周,随访半年。比较两组患者治疗后临床疗效、肠镜检查结果、复发情况及不良反应。结果:治疗8周后,观察组临床总有效率明显高于对照组(P<0.05);观察组内镜指数明显优于对照组(P<0.05),观察组不良反应低于对照组(P<0.05),随访6个月,观察组复发率明显少于对照组(P<0.05)。结论:参苓白术散口服联合柳氮磺胺吡啶灌肠治疗慢性复发型UC患者的能够更为有效缓解病情,促进溃疡愈合,且不良反应少,复发率低。
Objective: To investigate the curative effect of Shenling Baizhu San oral combined with sulfasalazine (SASP) enema in patients with chronic ulcerative colitis. Methods: 56 patients with chronic recurrent ulcerative colitis (UC) were randomly divided into observation group and control group, 28 cases in each. The observation group was treated with Shenlingbaizhu San oral (18g / d) and sulfasalazine enema (3g / d) for 8 weeks, followed up for six months. The control group was given sulfasalazine enema (3g / d) Follow-up for six months. The clinical efficacy, colonoscopy results, recurrence and adverse reactions of the two groups were compared. Results: After 8 weeks of treatment, the total effective rate in observation group was significantly higher than that in control group (P <0.05); the endoscopic index in observation group was significantly better than that in control group (P <0.05), and the adverse reactions in observation group were lower than those in control group <0.05), followed up for 6 months, the recurrence rate of the observation group was significantly less than that of the control group (P <0.05). Conclusion: Shenling Baizhu San combined with sulfasalazine enema in patients with chronic recurrent UC can relieve the disease more effectively and promote ulcer healing with less adverse reactions and low recurrence rate.